<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To date, case-control studies on the association between <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR) gene polymorphisms and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> have provided controversial results </plain></SENT>
<SENT sid="1" pm="."><plain>To clarify the effect of MTHFR polymorphisms on the risk of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, a meta-analysis of <z:hpo ids='HP_0000001'>all</z:hpo> case-control studies was performed </plain></SENT>
<SENT sid="2" pm="."><plain>The fixed effects and random effects model showed that the C677T polymorphism was associated with a risk of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> among Caucasian populations, and A1298C polymorphism was associated with a risk of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> among Asian populations </plain></SENT>
<SENT sid="3" pm="."><plain>Our pooled data suggest evidence for a major role of MTHFR polymorphisms in the <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>